Jefferies reiterates Sarepta stock rating on siRNA data outlook

Jefferies reiterated a Buy and $30 price target on Sarepta (SRPT); shares trade at $22.16 after a 76% decline over the past year and are near a 52‑week low of $10.41. Early Phase I/II siRNA data (SRP‑1001, SRP‑1003) showed dose‑dependent muscle exposure, biomarker reductions and favorable tolerability, and Jefferies expects MAD durability data and additional surrogate biomarkers in H2 2026. Company/analysts forecast a return to profitability with EPS of $4.06 for FY2026; regulatory catalysts include sNDA submissions by end‑April to convert Amondys/Vyondys accelerated approvals (FDA allows ESSENCE and RWE) with potential full approvals by Feb 2027, plus possible Elevidys sales rebound and Elevidys+sirolimus safety data in H2 2026.

Analysis

The market is effectively buying optionality on a platform rather than valuing recurring revenues, which raises two second-order consequences: (1) downstream suppliers of oligonucleotide/AAV manufacturing capacity become de facto leverage to any positive readthroughs, concentrating upside into CDMO balance sheets and capacity-constrained players; (2) payers and large hospital systems will be the gatekeepers to realized cash flows, so clinical/biomarker wins translate to valuation only if accompanied by clear durability and health-economic narratives.

Tail risks are asymmetric and time-structured. Near term (weeks–6 months) the biggest de-risk is binary regulatory clarity disclosures — either they widen the investor base or they expose endpoint uncertainty; medium term (6–24 months) the main reversal vector is durability or safety signals in larger cohorts and real-world use that materially reduce projected lifetime benefit, which would compress multiples by >50% in downside scenarios. Manufacturing bottlenecks and pricing/reimbursement pushback are persistent structural negatives that can erase peak expectations even if clinical endpoints hold.

From a positioning perspective, treat the equity as call-like optionality with meaningful idiosyncratic risk rather than a classic growth biotech. That argues for asymmetric, option-defined exposure and for pairing with sector hedges or long-only exposure to CDMOs that will monetize increased platform demand regardless of final label breadth. Monitor three triggers closely: definitive multi-dose durability readouts, regulatory guidance on evidence acceptability, and any material manufacturing fills/delays — each should prompt rebalancing rather than static hold decisions.

Key Decisions for Investors

• Long SRPT (ticker: SRPT) via 18–24 month call-spread: allocate 2–4% of fund's biotech sleeve; structure as buy LEAP call / sell higher strike call to cap premium; target 2.5–4x on positive durability/regulatory readthroughs, max loss = premium paid; enter within 30–90 days or on a ≤15% pullback.
• Paired trade: long SRPT (size 3%) / short XBI (size 1%) ratio 3:1 to hedge sector beta for 6–12 months; objective is to capture idiosyncratic upside while neutralizing broad biotech volatility; cut both legs if SRPT misses a major safety/durability signal.
• Buy 6–9 month puts on SRPT (small hedge, 0.5–1% of fund) when initiating or adding long exposure to protect against binary downside from adverse safety or regulatory setbacks; cost of puts should be viewed as insurance vs >50% downside scenarios.
• Long selected CDMO exposure (examples: LZAGY/CTLT) for 9–18 months with 3–5% allocation to play manufacturing/leverage; these names should outperform if platform uptake increases even without full commercial success for the company.